Saturday 17 October 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.41
0.53
−5.33%
Follow INKT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 37.00 | 10.90 | 8.50 | 4.63 | 4.56 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 221.55 | 49.40 | 33.40 | 19.00 | 76.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 31 | 33 | 37 | 31 | 23 | 15 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 1 | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (24) | (16) | (30) | (28) | (22) | (11) | (12) | |||||
| EBT margin, % | — | — | — | (3,451.60) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (24) | (16) | (30) | (28) | (22) | (11) | (12) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (9.89) | (6.74) | (11.60) | (8.30) | (6.50) | (2.86) | (2.93) | |||||
| Cash flow | — | — | — | (6.21) | (3.46) | (4.93) | (5.60) | (4.59) | (2.53) | (1.39) | |||||
| Capex | — | — | — | (0.18) | (0.04) | (0.10) | (0.07) | (0.02) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (6.39) | (3.50) | (5.02) | (5.68) | (4.61) | (2.53) | (1.39) | |||||
| Book value | — | — | — | (15.10) | (22.35) | 9.14 | (0.12) | (5.25) | (5.19) | (3.33) | |||||
| Shares, m | — | — | — | 2 | 2 | 3 | 3 | 3 | 4 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | — | — | — | — | — | — | ||||
| P/S | — | — | — | 0.00 | — | — | — | — | — | — | |||||
| P/B | — | — | — | 0.00 | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | 0.00 | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | (25.47) | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (15) | (8) | (13) | (19) | (16) | (10) | (6) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | — | — | — | (15) | (8) | (13) | (19) | (16) | (10) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (7) | (10) | 23 | 8 | (8) | (2) | 1 | ||||
| Total debt | — | — | — | 27 | 44 | — | — | — | 5 | — | |||||
| Net debt | — | — | — | 26 | 41 | (39) | (20) | (3) | 0 | (13) | |||||
| Shareholders’ equity | — | — | — | (36) | (54) | 24 | 0 | (18) | (20) | (14) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (3,636.98) | (553.84) | (134.89) | (90.71) | (172.59) | (209.96) | (125.20) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 52.77 | 36.00 | 200.76 | (239.49) | 243.36 | 57.30 | 73.90 | |||||
Negative figures in brackets.
Fiscal years to Dec 2019
Charts ten years each
MiNK Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $52.0M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| INKT MiNK Therapeutics, Inc. | $50.7M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | |
| LONA LeonaBio, Inc. | $49.8M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $49.8M | — (loss-making) | — (loss-making) | −43.79% (below 0%: shrinking) | n/m | −33.16% (below 0%: shrinking) | 100.00% | (1,690.39%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HYPD Hyperion DeFi, Inc. | $49.0M | — (loss-making) | 3.6× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $48.5M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| ELTX Elicio Therapeutics, Inc. | $48.2M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $49.6M | — | — | +106.16% | — | −12.19% | 0.00% | 0.00% |
MiNK Therapeutics, Inc. (INKT) key facts
- MiNK Therapeutics, Inc. (INKT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, INKT traded at $9.41, a market capitalization of $50.7 million.
- Return on equity was 73.9% and debt-to-equity 0.00.
MiNK Therapeutics, Inc. (INKT) Latest News
No news at this impact. Lower the threshold for more.